Viral Vector CDMOs — Ranked by Signal Score · 2026
· updated as new inspection, certificate, and trial data enters the platform
82
CDMOs tracked
60
Fully scored
18
With FDA records
53
FDA inspections
192
EMA/MHRA GMP certs
2
Warning letters
On CDMO Signal's composite Signal Score, Thermo Fisher Scientific, AGC Biologics, and Takeda lead the viral vector CDMO rankings — an aggregation across AAV, lentiviral, and adenoviral vector manufacturers. The Signal Score is a 0–100 composite of four weighted pillars — Quality Compliance (35%), Operations (25%), Financial Stability (20%), and Capacity Intelligence (20%) — built from FDA inspection history, EMA/MHRA GMP certificates, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. Vector platform is the first cut in any viral vector CDMO shortlist: AAV programs weight suspension platform maturity, serotype experience, and full/empty capsid analytics; lentiviral programs weight BSL-2 containment integrity, RCL testing, and titer + potency assay maturity; adenoviral programs weight yield, process comparability, and thermal stability. See the dedicated AAV, lentiviral, and adenoviral pages for platform-filtered rankings. Full methodology at cdmosignal.com/methodology.
Viral vector CDMOs manufacture the three GMP-relevant vector platforms used in modern gene therapy and gene-modified cell therapy: adeno-associated virus (AAV), lentivirus, and adenovirus. Each platform has distinct process, containment, and analytics requirements, and CDMOs typically specialize in one or two platforms rather than all three. Platform is the first shortlist filter in any viral vector procurement decision.
This ranking aggregates every CDMO tracked as a viral vector manufacturer across the three platforms. For platform-specific rankings with process-critical detail (BSL-2 containment for lentivirus, full/empty capsid analytics for AAV, high-titre transient expression for adenovirus), use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors integrating vector supply with downstream cell processing (CAR-T, gene-modified HSC), the <a href="/modality/cell-and-gene-therapy">cell & gene therapy view</a> extends this list with cell therapy CDMOs.
FDA inspection outcomes across these CDMOs: 20 NAI (no action), 31 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (50), United States (47), Denmark (35), Germany (18), Italy (15).
Last updated 2026-08-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
|
83.1 | 97.9 | 6 insp · 10 GMP | Available | 2 programs |
| 2 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 2 insp · 23 GMP | Available | 2 programs |
| 3 |
TK
Takeda
Boston, MA · Zurich, CH
|
80.5 | 99.3 | 4 insp · 18 GMP | — | 100 programs |
| 4 |
Lonza
Basel, Switzerland
|
78.2 | 95.1 | 2 insp · 8 GMP | — | 1 programs |
| 5 |
OX
Oxford Biomedica
Oxford, United Kingdom
|
77.1 | 100.0 | 0 insp · 13 GMP | Available | 7 programs |
| 6 |
CI
Cincinnati Children's Vector Production Facility
Cincinnati, OH
|
75.2 | 100.0 | 1 insp · 0 GMP | — | 1 programs |
| 7 |
NR
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
|
73.4 | 97.7 | 1 insp · 0 GMP | Available | 9 programs |
| 8 |
RT
ReiThera
Rome, IT
|
71.1 | 100.0 | 0 insp · 4 GMP | — | 1 programs |
| 9 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | 8 insp · 11 GMP | Limited | 0 programs |
| 10 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 11 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 12 |
AJ
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
|
85.6 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 13 |
LB
Lotte Biologics
Incheon, KR · Syracuse, NY
|
83.7 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 14 |
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
83.7 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 15 |
KB
KBI Biopharma
Durham, NC · Boulder, CO
|
83.5 | 100.0 | 1 insp · 1 GMP | Limited | 0 programs |
| 16 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
83.5 | 100.0 | 0 insp · 23 GMP | 0 programs | |
| 17 |
DH
Danaher (CGT Portfolio)
Washington, DC
|
81.5 | — | — | — | 0 programs |
| 18 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
81.0 | 98.8 | 4 insp · 8 GMP | — | 0 programs |
| 19 |
NW
Northway Biotech
Vilnius, LT; Waltham (MA), USA
|
80.8 | 100.0 | 0 insp · 8 GMP | Available | 0 programs |
| 20 |
OB
OmniaBio
Hamilton, ON
|
79.5 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 21 |
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | Available | 0 programs |
| 22 |
PG
ProBioGen
Berlin, DE
|
78.9 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 23 |
XP
eXmoor Pharma
Bristol, United Kingdom
|
78.7 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 24 |
BB
bluebird bio Manufacturing
Durham, NC
|
78.5 | — | — | — | 0 programs |
| 25 |
AA
Ascend Advanced Therapies
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 26 |
NG
NecstGen
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 27 |
ET
Exothera
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 28 |
CE
Celonic
Basel, Switzerland
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 29 |
AD
Advent Bioservices
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 30 |
BV
Biovian
Turku, Finland
|
78.0 | 99.7 | 1 insp · 4 GMP | — | 0 programs |
| 31 |
AG2
August Bioservices
San Carlos, CA
|
77.4 | 98.5 | 1 insp · 0 GMP | — | 0 programs |
| 32 |
VG
Viralgen Vector Core
San Sebastián, Spain
|
76.8 | 100.0 | 0 insp · 4 GMP | Available | 0 programs |
| 33 |
Catalent
Bagsværd, Denmark (operating under Novo Holdings; legacy US operations Somerset, NJ)
|
76.5 | 79.3 | 12 insp · 35 GMP | — | 0 programs |
| 34 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
75.1 | 79.3 | 1 insp · 0 GMP | Available | 0 programs |
| 35 |
CG
Cytiva (Mfg Services)
Marlborough, MA · Uppsala, SE
|
74.0 | — | — | — | 0 programs |
| 36 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
72.8 | 95.1 | 1 insp · 0 GMP | Limited | 0 programs |
| 37 |
VE
Vigene Biosciences
Rockville, MD
|
72.5 | — | — | — | 0 programs |
| 38 |
EM
Emergent BioSolutions (CGT)
Baltimore, MD
|
71.0 | — | — | — | 4 programs |
| 39 |
GZ
Genezen
Indianapolis, IN · Lexington, MA
|
70.7 | 84.1 | 3 insp · 0 GMP | Available | 0 programs |
| 40 |
IU
Indiana University Vector Production Facility
Indianapolis, IN
|
66.2 | — | — | — | 49 programs |
| 41 |
AN
Andelyn Biosciences
Columbus, OH
|
63.0 | — | — | Available | 0 programs |
| 42 |
UM
MassBiologics
Boston, MA
|
63.0 | — | 1 insp · 0 GMP | — | 0 programs |
| 43 |
RA
Recipharm Advanced Bio
Stockholm, Sweden (US operations: Watertown, MA; EU/global ATMP division of Recipharm AB)
|
63.0 | — | — | — | 0 programs |
| 44 |
FB
Forge Biologics
Columbus, OH
|
62.7 | — | — | 3 programs | |
| 45 |
MS
Made Scientific
Princeton, NJ
|
61.5 | — | — | — | 0 programs |
| 46 |
GF
GeneFab
Alameda, CA and South San Francisco
|
61.5 | — | — | Available | 0 programs |
| 47 |
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
|
60.5 | — | — | — | 0 programs |
| 48 |
CoJourney Inc.
Horsham, PA (US HQ); Hangzhou, China (primary GMP manufacturing)
|
60.0 | — | — | Limited | 0 programs |
| 49 |
AB
Asklepios BioPharmaceutical (AskBio)
Research Triangle, NC · San Sebastian, ES
|
59.7 | — | — | — | 10 programs |
| 50 |
TR
Takara Bio
Kusatsu, Shiga Prefecture, Japan
|
59.5 | — | — | — | 8 programs |
| 51 |
MA
Matica Biotechnology
College Station, TX
|
59.0 | — | — | Available | 0 programs |
| 52 |
VB
VintaBio
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 53 |
WB
Waisman Biomanufacturing
Madison, WI
|
59.0 | — | — | — | 0 programs |
| 54 |
EB
ElevateBio BaseCamp
Waltham, MA
|
59.0 | — | — | — | 0 programs |
| 55 |
CP
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
|
59.0 | — | — | — | 0 programs |
| 56 |
VM
Vector BioMed
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 57 |
AM
Anemocyte
Gerenzano, IT
|
59.0 | — | — | — | 0 programs |
| 58 |
HX
Helixmith
Seoul, KR
|
59.0 | — | — | — | 0 programs |
| 59 |
DINAMIQS
Schlieren (Zurich), Switzerland
|
59.0 | — | — | Available | 0 programs |
| 60 |
CV
CEVEC Pharmaceuticals
Cologne, DE
|
56.5 | — | — | — | 0 programs |
| — |
3P Biopharmaceuticals (now 3PBIOVIAN)
Pamplona-Noáin, Spain
|
Profiled | — | — | — | 0 programs |
| — |
VIVEbiotech
San Sebastián, Spain
|
Profiled | — | — | — | 0 programs |
| — |
Roche / Genentech (Internal Manufacturing & CustomBiotech)
Basel, Switzerland
|
Profiled | — | — | — | 0 programs |
| — |
Rose BioSolutions
Wilmington, MA
|
Profiled | — | — | — | 0 programs |
| — |
Orphan Therapeutics Accelerator (OTXL)
Cambridge, MA
|
Profiled | — | — | — | 0 programs |
| — |
Porton Advanced
Cranbury, NJ
|
Profiled | — | — | — | 0 programs |
| — |
Vantage Vector (Demo)
Gaithersburg, MD
|
Profiled | — | — | Available | 0 programs |
| — |
Advanced BioScience Laboratories, Inc. (ABL Inc.)
Rockville, MD
|
Profiled | — | — | — | 0 programs |
| — |
Spur Therapeutics
London, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Ultragenyx (UX111 — AAV, Sanfilippo Syndrome Type A)
Novato, CA
|
Profiled | — | — | — | 0 programs |
| — |
AAV Gene Therapy Programs (Industry-Wide)
N/A — Industry Pattern
|
Profiled | — | — | — | 0 programs |
| — |
Eppendorf BioBLU
Hamburg, Germany
|
Profiled | — | — | — | 0 programs |
| — |
AAV Gene Therapy — Purification-Driven Program Failures (Industry Pattern)
N/A — Industry-Wide Pattern
|
Profiled | — | — | — | 0 programs |
| — |
Landmark Bio
Watertown, MA
|
Profiled | — | — | — | 0 programs |
| — |
IDT Biologika GmbH
Dessau-Roßlau, Germany
|
Profiled | — | — | — | 0 programs |
| — |
Pharmaron Biologics (Liverpool)
Liverpool, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Canton Biologics Co., Ltd.
Foshan (Shunde District), China
|
Profiled | — | — | — | 0 programs |
| — |
Canton Biologics
Guangzhou, China
|
Profiled | — | — | — | 0 programs |
| — |
Novasep
Lyon, France
|
Profiled | — | — | — | 0 programs |
| — |
Kodo LifeScience Pvt. Ltd.
Valsad, Gujarat, India
|
Profiled | — | — | — | 0 programs |
| — |
Kodo Lifescience Private Limited
Vapi/Valsad, India
|
Profiled | — | — | — | 0 programs |
| — |
CdmoGen Co., Ltd.
Cheongju, South Korea
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Viral Vector CDMO
Vector platform match
First shortlist filter for any viral vector program is platform. AAV for in vivo systemic, lentiviral for ex vivo cell engineering, adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within.
Facility-level regulatory record on the platform
A CDMO's strong FDA record on AAV does not automatically de-risk their lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use, not the CDMO's aggregate score.
Analytics maturity per vector
Full/empty capsid separation for AAV, RCL testing for lentivirus, particle-to-infectivity ratio for adenovirus — each platform has non-negotiable release-testing requirements. A CDMO's qualified, validated assay panel for the specific vector is the single most under-appreciated cost driver in viral vector programs.
Capacity match to phase and dose
AAV early clinical runs at 50-200L, commercial at 1,000-2,000L single batch; lentiviral commercial supply is a narrower field with per-patient-dose economics. Confirm the CDMO's capacity headroom at your target phase before shortlisting — capacity constraints appear late and derail commercial launches.
Which viral vector platform does my program need?
The three GMP platforms map to distinct program types. AAV is the dominant delivery platform for in vivo gene therapy — rare disease, ophthalmology, neurology, cardiac, and musculoskeletal indications. It's non-integrating, made at 200-2,000L batch scale in suspension or adherent culture, and every approved in vivo gene therapy uses AAV. Lentivirus is the workhorse for ex vivo cell engineering — CAR-T, TCR, and gene-modified HSC programs use lentivirus to stably integrate the therapeutic gene into patient-bound cells. Lentiviral manufacturing runs at BSL-2 with mandatory replication-competent lentivirus (RCL) testing. Adenovirus retains relevance for vaccines and select gene therapy programs where high transient expression is acceptable — its non-integrating nature and strong immunogenicity make it well-suited for prime-boost vaccine architectures. Most CDMOs specialize in one or two platforms — filter by platform on the AAV, lentiviral, or adenoviral pages for the platform-specific shortlist.
What analytics differ across viral vector platforms?
Vector analytics drive lot release and directly determine batch success rate — they're the most under-appreciated cost driver in viral vector programs. AAV lot release requires titer (typically genome copies + capsid titer), full/empty capsid ratio (analytical ultracentrifugation, cIEF, or CDMS), aggregation, endotoxin, and increasingly potency assays that correlate with clinical activity. Lentivirus lot release requires infectious titer (usually functional/transducing units), vector copy number, replication-competent lentivirus (RCL) testing (a regulatory absolute), and residual host cell DNA/protein. Adenovirus lot release requires viral particle count, infectious titer, particle-to-infectivity ratio, and residual host cell proteins. CDMOs with qualified, established, and independently-validated assay platforms for the specific vector — not just the general capability to "run analytics" — meaningfully de-risk comparability and tech transfer.
How does CDMO Signal aggregate viral vector CDMOs?
The viral vector ranking is a union of CDMOs tagged with any of the three GMP-relevant vector platforms in our directory (AAV, lentiviral, adenoviral). Each CDMO appears once regardless of how many platforms they cover — a multi-platform manufacturer like Lonza, Thermo Fisher, or Catalent shows here at their composite Signal Score, and the individual platform pages break out platform-specific ranking positions. Signal Score is computed identically across all modalities; the aggregation doesn't inflate scores, it widens the candidate set.
Which viral vector CDMOs have commercial-approved product experience?
Manufacturing for approved viral vector products is the strongest possible buyer signal — it proves a facility has passed both a full BLA/MAA CMC review and a pre-approval inspection at commercial scale. Approved AAV gene therapies include Zolgensma (Novartis/AveXis, Novartis-manufactured then contract-manufactured), Luxturna (Spark, Novartis-manufactured), Roctavian (BioMarin), Elevidys (Sarepta, multiple CDMO partners); approved lentiviral cell therapies include Kymriah (Novartis), Yescarta (Gilead/Kite), Breyanzi (BMS), and bluebird bio's ex vivo gene therapies. CDMOs with named involvement in these programs carry demonstrated commercial posture. The Signal Score reflects this indirectly through inspection density and clinical footprint, but for late-stage program selection sponsors should cross-reference the individual CDMO profile pages with FDA approval history for direct evidence.
Viral Vector CDMOs — Frequently Asked Questions
Who are the top Viral Vector CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Viral Vector CDMOs include Thermo Fisher Scientific, AGC Biologics, Takeda. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Viral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 18 Viral Vector CDMOs with FDA inspection records and 192 EMA/MHRA GMP certificates across the group.
What should I look for in a viral vector CDMO?
Match the vector platform first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, vector-specific analytics maturity, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific technical detail worth reading before finalizing a shortlist.
How many viral vector CDMOs does CDMO Signal track?
65+ CDMOs are tracked across the three GMP viral vector platforms — the union of AAV, lentiviral, and adenoviral manufacturers, deduplicated. Each is scored independently on the standard four-pillar Signal Score composite.
How is viral vector manufacturing different from mAb or recombinant protein biologics?
Viral vector manufacturing shares the mammalian cell culture upstream backbone with biologics but diverges sharply on downstream. Viral vector downstream requires enveloped/non-enveloped virus purification (chromatography, tangential flow filtration, ultracentrifugation) rather than protein A affinity capture. Analytics differ fundamentally — infectious titer and capsid analytics for viral vectors vs product-related impurities for biologics. Regulatory paths also differ: viral vectors carry additional biosafety review (RCL for lentivirus, adventitious agents for all platforms) beyond standard biologics.
Related modalities